We are happy to share that we attended

"63° SIMPOSIO AFI - Le Sfide dell’Industria della Salute: Ricerca, Innovazione, Sostenibilità"

in Rimini, on 5-7 June 2024!

We have been an active part of this important event that has been engaging the international pharmaceutical industry stakeholders for more than 60 years. The Symposium is a valuable exchange moment among main players of scientific research community and pharma companies, biotechs and service providers.

We enjoyed a lot being involved into these high level discussions and fruitful brainstorming.

We attended the 35th CPHI Congress held in Milan on 8-10 October 2024!

CPHI Congress is always a great occasion to develop new meaningful connections with people and companies, to farm exhisting relationships and to open networking opportunities with endless chances to learn, innovate and reshape the future of pharma.
Isabella Barbieri, our Regulatory Affairs Director, and Giovanni Zampano, our International Regulatory Affairs Director, had the chance to participate to the sessions and to talk to many attendees but if you didn't manage to talk to them during the event, just reach out to them directly and ask for a meeting:

i.barbieri@rpngroup.com

g.zampano@rpngroup.com

CPHI Milan 2024 has been a notable success where over 62,000 industry professionals and 2,400 exhibitors showcased the latest in pharma innovation in drug development, biotech, and regulatory compliance to drive the future of healthcare.

RPN Group had the privilege of attending ISPOR Europe 2025, where the best minds in health economics and outcomes research (HEOR) come together to shape the future of healthcare. This year marks an incredible milestone—30 years of driving forward excellence in HEOR, and we’re proud to contribute to the conversations that are defining the next chapter in healthcare decision-making.

At this year’s congress, discussions around critical topics like JCA, MFN, and the evolving landscape of Market Access in Europe are sparking engaging debates and providing valuable insights into how we can improve healthcare delivery. The event also features inspiring poster sessions showcasing the latest research that’s transforming the industry.

The congress provided invaluable opportunities for networking, sharing insights, and collaborating on innovative approaches to improving healthcare delivery. From cutting-edge research to forward-thinking discussions, the event showcased how the field of HEOR continues to evolve and drive positive change.

We are excited to continue the conversations started at ISPOR Europe 2025 and look forward to furthering our work in advancing market access and healthcare outcomes globally.

If you haven't had the chance to meet our Lucia Piampiani, Market Access Director during the event, feel free to contact her direclty to arrange a tailored meeting.

BIO-Europe 2025 has officially wrapped up in Vienna, and what an incredible journey it was!

RPN was proud to be part of Europe’s premier biopharma partnering event, where over 5,700 professionals from 3,000+ companies across 60+ countries gathered to drive the future of life sciences. 🌍

Benedetta Montagnini, our Senior Manager of Business Development, represented RPN on-site, connecting with biotech and pharma leaders, sharing insights, and exploring exciting new collaborations.

We were thrilled to be part of the action at the Italian Pavilion—a space where conversations sparked, partnerships flourished, and the future of healthcare was shaped.

From innovation to strategy, BIO-Europe 2025 was a space where ideas flowed, and collaborations formed, with the promise of creating something truly transformative.

While the event has ended, the conversations, connections, and ideas are just getting started!

We’re excited for what lies ahead and are looking forward to continuing these dialogues throughout the year.

We can't wait to see everyone again next year at BIO-Europe 2026!

👉 Learn more about our services at rpngroup.com and follow us on LinkedIn to stay up to date.

As we conclude three dynamic days at CPHI, we reflect on an event that was nothing short of inspiring. From exploring the latest advancements in innovation and sustainability to engaging in thought-provoking discussions about the future of the pharmaceutical industry, this year's CPHI provided a platform for collaboration and progress on a global scale.

The energy was palpable, with meaningful conversations taking place across all sectors—from compliance to clinical development. Whether you were looking to share insights, discover new solutions, or build lasting partnerships, CPHI was the place to be. It was exciting to connect with industry leaders, innovators, and like-minded professionals, all of whom are helping to shape the future of pharma.

We were thrilled to have Isabella and Benedetta on-site in Frankfurt, meeting with partners and collaborators. If you didn't have the chance to meet them, we’d love to hear from you! Reach out directly to explore potential opportunities and continued collaborations.

Looking ahead, we’re already buzzing with excitement for CPHI 2026 in Milan. This will be an incredible opportunity to continue the momentum of innovation and partnerships—right in our home country. We can’t wait to see you all there and continue building on the connections we’ve made this year.

Until next time, thank you to everyone who made this year's CPHI a success. See you in Milan!

👉 Learn more about our services at rpngroup.com and follow us on LinkedIn to stay up to date.

We had a fantastic time at RAPS Convergence 2025 connecting with regulatory professionals from around the World! A big thank you to everyone who stopped by to meet our team and talk regulatory and market access strategies.

👏 Shoutout to Benedetta Montagnini and Lucia Piampiani for representing RPN Group and sharing our mission to support life sciences companies with tailored regulatory, market access, quality, and compliance solutions.

We’re proud to be part of such a forward-thinking community — see you at the next one!

👉 Learn more about our services at rpngroup.com and follow us on LinkedIn to stay up to date.

RPN was proud to take part in the Italian Pharmacovigilance Day 2025, held on October 1st in Verona — a key event dedicated to the latest developments, challenges, and innovations in the field of pharmacovigilance.

Representing RPN, Riccardo Chiarini (EU/EEA QPPV, Drug Safety & Quality Senior Manager) and Francesca Spera (Regulatory Affairs & Drug Safety Manager) joined fellow industry professionals for a day of insightful discussions focused on drug safety, regulatory evolution, and patient care.

As a company committed to regulatory excellence and patient safety, we value opportunities like this to exchange knowledge, strengthen professional connections, and stay at the forefront of pharmacovigilance trends.

We look forward to continuing the conversation and advancing best practices in drug safety with everyone who contributed to this engaging and forward-looking event.

Our Market Access Senior Manager Claudia Garimberti and our HEOR & Market Access Specialist Clelia Calandriello were delighted to attend the 4th GIRF National Congress, this year held in Florence from June 30th to July 1st!

As professionals dedicated to Health Economics and Outcomes Research, we were honored to be part of this important event organized by ISPOR Italy – Rome Chapter and the ISPOR Rome for Future Group. After the great success of previous editions, the congress confirmed itself as a key opportunity to:

* Explore emerging challenges in the pharmaceutical sector
* Exchange ideas among young professionals, institutions, academia, and industry
* Drive innovation through multidisciplinary networking.

We were proud to be selected for a poster presentation:

📌 Title: Negotiation for Inclusion in the List Established by Law 648/96: An Analysis of Medicines for Rare Diseases in the 2022–2024 Period

Authors: Chiara Pieve, Claudia Garimberti, Maria Sanna, Clelia Calandriello, Salvatore Pirri, Lucia Piampiani

🔍 The poster explores the application of Italian Law 648/96, which allows the reimbursement by the National Health Service (SSN) of innovative medicines not yet authorized in Italy but already approved abroad, those in clinical trials, or used for off-label indications. Our analysis highlights the negotiation process with AIFA when a significant economic impact is anticipated.

👉 If you're interested in HEOR and haven't had the opportunity to meet RPN crew yet, feel free to contact us to schedule a quick introductory call!

Our team has been delighted to be active part of the 64th AFI Symposium, which took place on June 11–13, 2025, in Rimini, Italy.

👤 Isabella Barbieri - Regulatory Affairs Director
👤 Valentina Ciurlia - Regulatory Affairs Senior Manager
👤 Lucia Piampiani - Market Access Director

attended this premier event, a cornerstone for the Italian Pharmaceutical Industry bringing together professionals to explore the latest advancements and challenges in healthcare.

🧠 The symposium covered critical topics, including:

🔹 Digital Health: Exploring the evolution of the pharmaceutical landscape with the introduction of technologies like AI and digital medical devices
🔹Manufacturing: Innovations and future developments in pharmaceutical manufacturing.
🔹Raw Materials: Market dynamics and challenges in managing APIs and excipients.
🔹Advanced Therapies: New frontiers in biotech and personalized medicine.
🔹Regulatory Evolution: The digitalization of product information leaflets and its implications.

If you didn't manage to talk to them during the event or missed the Symposium at all, do not hesitate to contact them and discuss how we can shape the future of healthcare together.